Peng Zhan, Wenjun Li, Hongfei Chen and Xinyong Liu Pages 3393 - 3409 ( 17 )
In recent years, the number of useful chemical biology information of protein-protein interactions in the HIV life cycle and related inhibitors, is growing rapidly, which makes protein-protein interactions a new investigative area for antiviral drug intervention. This review will summarize recent work in this field, mainly focusing on the utilization of small molecules targeted against a variety of protein-protein interactions that have great therapeutic feasibility for HIV infection, and lastly outline some other important protein-protein interactions with a potential to advance into novel anti- HIV drug targets in future.
HIV,AIDS,drug design,drug targets,protein-protein interactions,inhibitor,Anti-HIV,anti-AIDS,reverse transcriptase,protease,integrase,CCR5 coreceptor,HAART),capsid protein,NF-B,Rev protein,RNase H,TEFb,allosteric site,GP120,–,CD4,(ELISA),Schiffs base linkage,Bris-tol-Myers Squibb,clinical trials,HIV-1 inhibition,MAPPIT,HIV enzymes,Dimerization Inhibitors,HIV therapy,peptidomimetics,PR dimerization inhibitors,SAR,VIF-APOBEC3G,LEDGF/p75,CHIBA-3003,SQs,cell-based assays,(Vpr),Gag,GAG-TSG101,CRM1-NES
, , , Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, Shandong, P.R., China